Baxter’s Gammagard Shows Alzheimer’s Benefit in Study

Baxter International Inc.’s Gammagard, used to treat immune system disorders, halted the progression of Alzheimer’s disease for as long as three years in a trial of 16 patients, researchers said.

In the study, four patients given the ideal dose at the start of the trial experienced lasting improvement. Five patients initially given a placebo and seven others on varying amounts of Gammagard, experienced no benefit until they were switched to the right dose, according to the research presented at the Alzheimer’s Association’s annual meeting in Vancouver.